Abstracts tagged "prevention"

Abstract Number: 1932 • ACR Convergence 2025
Evaluating a Potential Cause of Excess Lung Cancer Mortality in RA: An Analysis of Chest CT Imaging Frequency in RA
Rebecca Brooks¹, Sara Achenbach², Vanessa Kronzer¹, Bryant England³, Emily Leasure¹, Elena myasoedova¹, John Davis¹ and Cynthia Crowson⁴, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, ³University of Nebraska Medical Center, Omaha, NE, ⁴Mayo Clinic, Stewartvillle, MN
Background/Purpose: Recent studies have demonstrated that patients with RA are at an increased risk for the development of lung cancer and lung cancer related death.…
Abstract Number: 1008 • ACR Convergence 2025
Nationwide Historical Cohort Study on the Primary Prophylactic Effects of Colchicine in Cardiovascular Events
Hasan Satis¹, Umut Kalyoncu², Gizem Ayan³, Ali Aykut Fidanci⁴, Mustafa Mahir Ulgu⁴, Naim Ata⁴, Suayip Birinci⁴, Mehmet Koçak⁵ and Ahmet Gul⁶, ¹University of Health Sciences, Abdurrahman Yurtaslan Oncology Hospital, Rheumatology, Ankara, Turkey, ²Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey, Ankara, Turkey, ³Ankara Research and Training Hospital, Ankara, Turkey, ⁴Ministry of Health, Ankara, Turkey, ⁵Medipol University, Istanbul, Turkey, ⁶Istanbul University, Istanbul, Turkey
Background/Purpose: While two trials with colchicine have demonstrated its efficacy in reducing the risk of cardiovascular events, a more recent study showed no significant impact…
Abstract Number: 1928 • ACR Convergence 2025
Oral Health in Patients with Rheumatic Diseases: A Pilot Quality Improvement Program
Margarita Isabel Alarcon-Jarquin¹, Fernanda M. Garcia-Garcia², Vanessa L. Lopez-Flores¹, Aleydis Gonzalez-Melendez³, Gabriel Figueroa-Parra³, Dionicio A. Galarza-Delgado² and Janett C. Riega-Torres⁴, ¹Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ²Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ³Rheumatology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ⁴Rheumatology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico
Background/Purpose: Patients with rheumatic diseases commonly experience oral health issues such as dental caries, xerostomia, and periodontal disease. These complications are linked to both the…
Abstract Number: 0967 • ACR Convergence 2025
Single-Cell RNA Sequencing Reveals a Prominent Pro-Inflammatory Gene Signature of Dermal Fibroblasts in Pre-Stages of SSc
Lumeng Li¹, Elena Pachera², Rucsandra Dobrota³, Sinziana Muraru⁴, Kristina Bürki³, Carina Mihai⁵, Muriel Elhai⁶, Laura Much⁷, Astrid Hofman³, Pietro Bearzi¹, Anna-Maria Hoffmann-Vold⁸ and Oliver Distler⁹, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zürich, Switzerland, ²University Hospital Zurich, Zurich, Switzerland, ³Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zurich, Switzerland, ⁴University of Zurich, University Hospital Zurich, Zürich, Switzerland, ⁵University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁶University Hospital zurich, Zürich, Switzerland, ⁷Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁸Oslo University Hospital, Oslo, Norway, ⁹Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: The poor prognosis of SSc patients demands an urgent need to prevent disease onset. Recently, we reported a global pro-inflammatory gene signature of dermal…
Abstract Number: 1911 • ACR Convergence 2025
Characterizing Psoriasis Patients at Risk for Transition to Psoriatic Arthritis: Early Insights from the STOP PsA At-Risk Cohort
Victoria Konzett¹, Eva Manger², Simon Reider², Johannes Griss³, Constanze Jonak³, Kastriot Kastrati⁴, Peter Mandl⁴, Gudrun Ratzinger⁵, Christina Duftner², Thomas Karonitsch⁴ and Daniel Aletaha⁶, ¹Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Department of Internal Medicine, Clinical Division of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria, ³Department of Dermatology, Medical University of Vienna, Austria, Vienna, Austria, ⁴Department of Medicine III, Division of Rheumatology, Medical University Vienna, Vienna, Austria, ⁵Department of Dermatology, Venereology and Allergology, Medical University of Innsbruck, Austria, Innsbruck, Austria, ⁶Medical University Vienna, Wien, Austria
Background/Purpose: Psoriatic arthritis (PsA) develops predominantly in patients with psoriasis (Pso). Although key drivers and predictors of disease progression have been identified in recent years,…
Abstract Number: 0673 • ACR Convergence 2025
Association Between Vasoactive-Vasodilating Therapy and Reduced Detection of Pulmonary Arterial Hypertension in Systemic Sclerosis: Evidence From a EUSTAR Study
Nicola Farina¹, Silvia Bellando-Randone², SEBASTIEN SANGES³, hilde Bjørkekjær⁴, lorenzo tofani⁵, Marie-Elise Truchetet⁶, Vanessa Smith⁷, Andra Balanescu⁸, Christina Bergmann⁹, Yannick Allanore¹⁰, Philipp Klemm¹¹, simona Truglia¹², Luca Idolazzi¹³, Christopher Denton¹⁴, Roberta Foti¹⁵, anna Wojteczek¹⁶, Emmanuel Chatelus¹⁷, Madelon Vonk¹⁸, Serena Guiducci¹⁹, David Launay²⁰, Eric Hachulla²¹, Jeska de Vries-Bouwstra²², Anna-Maria Hoffmann-Vold²³, Marco Matucci-Cerinic²⁴, Oliver Distler²⁵ and Cosimo Bruni²⁶, ¹Department of Experimental and Clinical Medicine, Scleroderma Unit, Division of Rheumatology, University of Florence, Azienda Ospedaliera Universitaria Careggi, Florence, Italy. Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan, Italy, Milan, Italy, ²University of Florence, Florence, Florence, Italy, ³Medecine Interne CHRU Lille, Lille, France, ⁴Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, olso, Norway, ⁵Department of Statistics, Informatics and Applications, University of Florence, Florence, Italy, firenze, Italy, ⁶Bordeaux University Hospital, Bordeaux, France, ⁷Ghent University Hospital, Gent, Belgium, ⁸UNIVERSITY OF MEDICINE AND PHARMACY CAROL DAVILA, Bucharest, Romania, ⁹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ¹⁰Université Paris Cité, Paris, France, ¹¹Department of Rheumatology and Clinical Immunology Center, JLU Giessen, Campus Kerckhoff, Bad Nauheim, Germany, Bad Nauheim, Germany, ¹²Reumatologia, Azienda Ospedaliero-Universitaria Policlinico Umberto I, Rome, Italy, rome, Italy, ¹³Section of Rheumatology, Department of Medicine, University of Verona, Verona, Italy, verona, Italy, ¹⁴University College London, UK, London, United Kingdom, ¹⁵Division of Rheumatology, A.O.U. Policlinico-San Marco, Catania, Italy, Catania, Italy, ¹⁶Department of Rheumatology, Clinical Immunology, Geriatrics and Internal Medicine, Medical University of Gdańsk, University Clinical Centre, Gdańsk, Poland, Gdańsk, Poland, ¹⁷Department of Rheumatology, University Hospital Strasbourg, France, Strasbourg, France, ¹⁸Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹⁹Department of Experimental and Clinical Medicine, Scleroderma Unit, Division of Rheumatology, University of Florence, Azienda Ospedaliera Universitaria Careggi, Florence, Italy, Pistoia, Italy, ²⁰Univ. Lille, Inserm, CHU Lille, Department of Internal Medicine and Clinical Immunology, Reference Center for Rare Autoimmune and Autoinflammatory diseases (CERAINOM), U¹²⁸⁶ - INFINITE - Institute for Translational Research in Inflammation, Lille, France. National Reference Center for Pulmonary Arterial Hypertension (Pulmotension), Lille, France, Lille Cedex, France, ²¹University of Lille, LILLE, France, ²²Leiden University Medical Center, Leiden, Netherlands, ²³Oslo University Hospital, Oslo, Norway, ²⁴University San Raffaele Milano, Milano, Milan, Italy, ²⁵Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, ²⁶University of Zurich, Zurich, Switzerland
Background/Purpose: Vasoactive-vasodilating drugs (VVD) are the cornerstone of the treatment of pulmonary arterial hypertension (PAH), a form of precapillary pulmonary hypertension (pPH) that represents a…
Abstract Number: 1678 • ACR Convergence 2025
Abatacept in individuals at risk of developing rheumatoid arthritis: results from the Arthritis Prevention in the Pre-clinical Phase of RA with Abatacept Long Term Outcomes (ALTO) Study
Andrew Cope¹, Joana Vasconcelos¹, Marianna Jasenecova², Andrew Filer³, Karim Raza⁴, Sumera Qureshi¹, Maria Antonietta D'Agostino⁵, Iain McInnes⁶, Stefan Siebert⁶, John Isaacs⁷, Arthur Pratt⁸, Benjamin A. Fisher⁹, Christopher Buckley¹⁰, Paul Emery¹¹, Kulveer Mankia¹¹, Pauline Ho¹², MAYA BUCH¹³, Coziana Ciurtin¹⁴, Dirkjan van Schaardenburg¹⁵, Tom Huizinga¹⁶, René Toes¹⁶, Caroline Murphy¹ and A. Toby Prevost¹, ¹King's College London, London, United Kingdom, ²King's College London, London, ³The University of Birmingham, Birmingham, United Kingdom, ⁴University of Birmingham, Birmingham, United Kingdom, ⁵Division of Rheumatology and Clinical Immunology - Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁶University of Glasgow, Glasgow, United Kingdom, ⁷Newcastle University, Newcastle upon Tyne, United Kingdom, ⁸University of Newcastle, Newcastle, United Kingdom, ⁹King’s College London, London, UK; Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK, Birmingham, United Kingdom, ¹⁰University of Oxford, Oxford, United Kingdom, ¹¹University of Leeds, Leeds, England, United Kingdom, ¹²The Kellgren Centre for Rheumatology, Manchester Royal Infirmary, Manchester, United Kingdom, ¹³UNIVERSITY OF MANCHESTER, MANCHESTER, United Kingdom, ¹⁴University College London, London, ¹⁵Amsterdam UMC, Amsterdam, Netherlands, ¹⁶Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Clinical trials aimed at delaying or preventing rheumatoid arthritis (RA) in individuals at risk have been published with variable results. In the APIPPRA study,…
Abstract Number: 0619 • ACR Convergence 2025
Interim Analysis of the Impact of a Recombinant Herpes Zoster Vaccine on Systemic Lupus Erythematosus: A Randomized Controlled Study on Immunogenicity, Safety and Immunosuppressor Effects
Luciana Parente Costa Seguro¹, Andrea Negrini², Sandra G Pasoto³, Nadia E Aikawa⁴, Ana C Medeiros-Ribeiro³, Eduardo Borba¹, Emily Figueiredo Neves Yuki⁵, Artur Sartori², Danieli Andrade⁶, Thiago Freitas⁷, Henrique Giardini⁷, Clovis Artur Silva⁸ and Eloisa Bonfa¹, ¹Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, ²Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil, Sao Paulo, Sao Paulo, Brazil, ³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ⁴Pediatric Rheumatology Unit, Instituto da Criança e do Adolescente, Hospital das Clinicas HCFMUSP, Sao Paulo, Brazil., Sao Paulo, Sao Paulo, Brazil, ⁵Faculdade de Medicina da USP, São Paulo, São Paulo, Brazil, ⁶University of Sao Paulo, São Paulo, São Paulo, Brazil, ⁷Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, Brazil, ⁸University of São Paulo, São Paulo, São Paulo, Brazil
Background/Purpose: SLE patients are at increased risk of infections, including herpes zoster (HZ). Prior studies evaluating the recombinant herpes zoster vaccine (RZV) in SLE have…
Abstract Number: 1674 • ACR Convergence 2025
A Phase 2, Randomized, Placebo-Controlled Trial of Hydroxychloroquine in Individuals At-Risk for Future Rheumatoid Arthritis
Kevin Deane¹, Christopher Striebich², Marie Feser³, James O'Dell⁴, Judith James⁵, Jeffrey Sparks⁶, John Davis⁷, Jonathan Graf⁸, Maureen McMahon⁹, Elizabeth Solow¹⁰, Lindsy Forbess¹¹, Athan Tiliakos¹², Elena Schiopu¹³, David Fox¹⁴, Maria I. ("Maio") Danila¹⁵, Diane Horowitz¹⁶, Jonathan Kay¹⁷, Colin Strickland³, Joel Guthridge⁵, Cristina Arriens⁵, Jennifer Grossman¹⁸, Kristen Demoruelle¹⁹, Elizabeth Bemis³, Ashley Frazer-Abel³, Chelsie Fleischer²⁰, Ted Mikuls⁴, Melissa Greenleaf²¹, Kate York²², Sarah Walker²³, Lynette Keyes-Elstein²³, Margie Byron²³, Janel Fedler²⁴, Ellen Goldmuntz²⁵ and V. Michael Holers²⁶, ¹University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ²University of Colorado, Aurora, CO, ³University of Colorado Anschutz Medical Campus, Aurora, CO, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Mayo Clinic, Rochester, MN, ⁸UCSF, San Francisco, CA, ⁹UCLA David Geffen School of Medicine, Los Angeles, CA, ¹⁰UT Southwestern Medical Center, Dallas, TX, ¹¹Cedars-Sinai Medical Center, Los Angeles, CA, ¹²Emory University, Roswell, GA, ¹³Medical College of Georgia at Augusta University, Martinez, GA, ¹⁴University of Michigan, Dexter, MI, ¹⁵University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL, ¹⁶Northwell Health, Jericho, NY, ¹⁷UMass Chan Medical School, Worcester, MA, ¹⁸UCLA, Sherman Oaks, CA, ¹⁹University of Colorado Anschutz Medical Campus, Golden, CO, ²⁰University of Colorado Denver, Aurora, CO, ²¹National Institutes of Health, Rockville, MD, ²²Rho, Inc, Durham, NC, ²³Rho, Inc., Durham, NC, ²⁴Rho, Inc., Salem, IA, ²⁵NIAID/ NIH, Washington, DC, ²⁶University of Colorado, Denver, CO
Background/Purpose: Individuals with elevations of serum anti-cyclic citrullinated peptide (anti-CCP) antibodies are at-risk for rheumatoid arthritis (RA). Identification of interventions to prevent RA in anti-CCP-positive…
Abstract Number: 0576 • ACR Convergence 2025
Factors impacting progression from oligoarticular to polyarticular PsA: Data from the FOREMOST study
Laura Coates¹, Philip J. Mease², Joseph Merola³, Lourdes Perez Chada⁴, Dafna D. Gladman⁵, Alen Zabotti⁶, Ulrich Mrowietz⁷, mitsumasa kishimoto⁸, Cynthia Deignan⁹, Siddharth Chaudhari¹⁰, Lichen Teng¹¹ and Laure Gossec¹², ¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ²Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ³UT Southwestern Medical Center, Dallas, TX, ⁴Harvard Medical School, Wayland, MA, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁶Division of Rheumatology, Department of Medicine (DMED), Academic Hospital "Santa Maria della Misericordia", ASUFC, University of Udine, Udine, Italy, Udine, Italy, ⁷Department of Dermatology, University Medical Center Schleswig-Holstein, Kiel, Germany, ⁸Kyorin University School of Medicine, Tokyo, Japan, ⁹Amgen, Inc., Agoura Hills, CA, ¹⁰Amgen Inc., Thousand Oaks, CA, ¹¹Amgen Inc., Thousand Oaks, ¹²Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France
Background/Purpose: FOREMOST (NCT03747939)1 offers novel insights on early oligoarticular (oligo, ≤4 active joints) PsA. Our aim was to analyse progression to polyarticular (poly; >4 active…
Abstract Number: 1480 • ACR Convergence 2025
Urinary Biomarkers Detect Proliferative Lupus Nephritis in SLE Patients with Subclinical Proteinuria.
CHEN-YU LEE¹, Rufei Lu², Carla Guthridge², Wade DeJager³, Jennifer Barnas⁴, Jennifer Anolik⁵, H Michael Belmont⁶, Judith James², Jill Buyon⁷, Brad Rovin⁸, Michelle Petri⁹, Joel Guthridge² and Andrea Fava¹, ¹Johns Hopkins University, Baltimore, MD, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, ⁴University of Rochester, Rochester, NY, ⁵University of Rochester Medical Center, Rochester, NY, ⁶NYU School of Medicine, New York, NY, ⁷NYU Grossman School of Medicine, New York, NY, ⁸The Ohio State University, Columbus, OH, ⁹Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Early treatment is critical to prevent irreversible kidney damage in lupus nephritis (LN). Current guidelines recommend kidney biopsy when the urine protein-to-creatinine ratio (UPCR)…
Abstract Number: 0382 • ACR Convergence 2025
Preventative Health Screening Practices Among 666 Women with Systemic Rheumatic Diseases from the Hospital for Special Surgery Rheumatology Women’s Reproductive Health and Wellness Cohort: A Cross-Sectional Analysis
Sandhya shri Kannayiram¹, Amaya Smole², Lucy Masto³, Yongjay Kim⁴, Neha Nagpal¹, Naiva Manuela Piatchou Donfack¹, Deanna Jannat-Khah¹, Lisa Mandl¹, Sarah Lieber¹, Caroline Siegel¹, Michael Lockshin⁵, Lisa Sammaritano¹ and Medha Barbhaiya¹, ¹HOSPITAL FOR SPECIAL SURGERY, New york, NY, ²Hospital for Special Surgery, Brooklyn, NY, ³Hospital for Special Surgery, San Francisco, CA, ⁴Hospital for Special Surgery, Englewood Cliffs, NJ, ⁵Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Timely preventative health screenings in women with systemic rheumatic diseases (SRDs), especially those with other chronic conditions or who are on immunosuppressive therapy, may…
Abstract Number: 1447 • ACR Convergence 2025
Long-term impact of secukinumab on the prevention of psoriatic arthritis in patients with psoriasis: a 5-year pooled analysis of the ERASURE, FIXTURE and SCULPTURE studies
Ulrich Mrowietz¹, Laura Coates², Diamant Thaçi³, Mark Lebwohl⁴, Bardur Sigurgeirsson⁵, Richard B. Warren⁶, Richard G. Langley⁷, Andreas Clemens⁸, Cynthia Vizcaya⁸, Weibin Bao⁹, Kim Hoyt¹⁰, Lara Gómez¹¹ and Robert Bissonnette¹², ¹Department of Dermatology, University Medical Center Schleswig-Holstein, Kiel, Germany, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ³Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, ⁴Icahn School of Medicine at Mount Sinai, New York, NY, ⁵University of Iceland, Faculty of Medicine, Department of Dermatology,, Reykjavik, Iceland, ⁶Dermatology Centre, Northern Care Alliance, NHS Foundation Trust & Division of Musculoskeletal and Dermatological Sciences, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, ⁷Dalhousie University, Halifax, NS, Canada, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Novartis Pharmaceuticals Corporation, Hanover, NJ, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹¹Novartis Farmaceutica, Madrid, Spain, ¹²Innovaderm, Montreal, Québec, Canada
Background/Purpose: Secukinumab is a fully human monoclonal antibody that selectively inhibits interleukin-17A, demonstrating robust and sustained efficacy in moderate to severe psoriasis (PsO) and psoriatic…
Abstract Number: 0366 • ACR Convergence 2025
Dental Findings in Patients With Rheumatic Diseases and Its Association With Self-Perceived Oral Health
Fernanda M. Garcia-Garcia¹, Margarita Isabel Alarcon-Jarquin², Vanessa L. Lopez-Flores², Gabriel P. Castro-Cruz³, Carlos I. Estrada-Anguiano³, Jennifer Garcia-Bravo³, Aleydis Gonzalez-Melendez³, Gabriel Figueroa-Parra³, Dionicio A. Galarza-Delgado¹ and Janett C. Riega-Torres⁴, ¹Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ²Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ³Rheumatology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ⁴Rheumatology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico
Background/Purpose: Oral health conditions are frequent in patients with rheumatic diseases and can impact daily function and quality of life. Factors such as chronic inflammation…
Abstract Number: 2653 • ACR Convergence 2025
First Prospective Evaluation of Recombinant Herpes Zoster Vaccine in Systemic Sclerosis: Immunogenicity, Safety, and Disease Activity Outcomes
Ana Paula Luppino-Assad¹, Renata P Mello², Ana C Medeiros-Ribeiro³, Nadia E Aikawa⁴, Sandra G Pasoto³, Leonard V Kupa⁵, Renata Miossi⁶, Percival D Sampaio-Barros⁶, Eduardo Borba⁷, Eloisa Bonfa⁷ and Clovis Artur Silva⁸, ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SAO PAULO, Brazil, ²Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Sao Paulo, Brazil, ³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ⁴Pediatric Rheumatology Unit, Instituto da Criança e do Adolescente, Hospital das Clinicas HCFMUSP, Sao Paulo, Brazil., Sao Paulo, Sao Paulo, Brazil, ⁵Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, Sao Paulo, Brazil, ⁶Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, ⁷Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, ⁸University of São Paulo, São Paulo, São Paulo, Brazil
Background/Purpose: Systemic sclerosis (SSc) patients are at higher risk of herpes zoster (HZ) due to underlying immune dysregulation and immunosuppressive therapies. Vaccination is a key…

1
2
3
…
15
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].